RASA1 and prostate adenocarcinoma: Deletions and nonsynonymous mutations (including many truncating mutations; Figure 1A) of RASA1 are frequently observed in many large-scale integrative cancer studies listed in cBioPortal, such as 13% in metastatic castration-resistant prostate adenocarcinoma [30], 8.8% in uterine endometrial carcinoma [31], and 6.7% in lung squamous cell carcinoma [32].